Exploiting Need for Commercial Antibody Arrays, Fluidigm, Pierce, DBI, Others to Offer New Tools | GenomeWeb

Looking to meet the needs of the emerging market for antibody microarrays, at least four companies are launching or are planning to launch commercial antibody arrays or corresponding tools by the end of this quarter.

Though the new products vary in technology and applicability, the focus of those companies playing in the nascent space appears to be to offer researchers access what has been thought of as an exclusive technology, while enabling them to customize their own content.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.